A new report shows the top 10 causes of death in America in 2023, with one cause of death dropping several places down the list, according ...

Exercise is a cornerstone in managing metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study ...

Besides weight loss, exercise can aid in reducing liver fat, improving inflammation biomarkers, and enhancing cardiovascular ...

Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according to a study ...

Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...

Asia-Pacific leaders in liver cancer treatment gather at LEAD (Liver Experts for Advancing Liver Disease Diagnosis and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Coronary artery disease (CAD) is common in patients with cirrhosis, but cirrhosis itself is not significantly associated with ...

Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

The global cirrhosis management market is projected to grow from US$ 725 million in 2023 to US$ 1,052.3 million by 2033, with ...

Galectin Therapeutics (GALT) stock drops 25% as NAVIGATE trial for belapectin in liver disorder MASH fails to meet main goal.